Outlook Therapeutics (OTLK) Gross Margin (2025)

Outlook Therapeutics (OTLK) reported Gross Margin of 1098.52% for Q3 2025, up 1451.97% quarter-over-quarter from 70.78% in Q2 2025.

Outlook Therapeutics (OTLK) Gross Margin (2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 1 years of Gross Margin data on file, last reported at 1098.52% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 79.04%
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 86.85%
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 1,098.52%
Jun 30, 2025 70.78%